Doctor-reported hospital management of acute coronary syndrome in China: A nationwide survey of 1029 hospitals in 30 provinces

Yiping Chen, Lixin Jiang, Qiuli Zhang, Xiaoshuai Wei, Xi Li, Margaret Smith, Zhengming Chen

China Oxford Centre for International Health Research, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.

DOI: 10.4236/wjcd.2012.23029                

Abstract

Background: Despite recent improvements in the hospital treatment of ACS, little is known about current cardiological practice in China or use of evidence-based approach in Chinese hospitals. Methods: A questionnaire about doctor-reported hospital management of ACS was posted to the head of the cardiology department of 1397 hospitals across 30 provinces of China. Reported use of various clinical procedures and treatments were analysed and compared between different types of hospital. Results: Of the 1029 (74%) hospitals that responded, 43% were tier III (tertiary) hospitals. For STEMI, primary PCI was used as the main reperfusion therapy by 50.2% of tier III and 9.3% of tier II/I (secondary) hospitals. Most of hospitals also used various proven therapy routinely for STEMI and NSTEMI/UA, including anti-platelet therapy (98% and 93%), anticoagulant (96% and 90%), statin (97% and 94%), oral β-blockers (87% and 86%) and ACE-I (88% and 83%). However, certain therapies with little or no proven value (eg, G.I.K., magnesium and Chinese tradition medicine) remained used routinely by 25% - 40% of tier II/I hospitals. After discharge, statin, antiplatelet, β-blockers and ACE-I were reportedly used routinely by 85% - 95% of the responders for secondary prevention. Conclusions: With a few exceptions, doctor-reported hospital management of ACS in China is largely consistent with that recommended by current guidelines. Large nationwide registries are needed to assess long-term adherence to treatments after hospital discharge.

Keywords

ACS; In-Hospital Treatments; Secondary Prevention; General Management; China

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Wijeysundera, H.C., Machado, M., Farahati, F., et al. (2010) Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. Journal of the American Medical Association, 303, 1841-1847. doi:10.1001/jama.2010.580
[2]	Capewell, S., MacIntyre, K., Stewart, S., et al. (2001) Age, sex, and social trends in out-of-hospital cardiac deaths in Scotland 1986-95: A retrospective cohort study. Lancet, 358, 1213-1217. doi:10.1016/S0140-6736(01)06343-7
[3]	Ford, E.S., Ajani, U.A., Croft, J.B., et al. (2007) Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. The New England Journal of Medicine, 356, 2388-2398. doi:10.1056/NEJMsa053935
[4]	Wu, Z., Yao, C., Zhao, D., et al. (2001) Sino-MONICA project: A collaborative study on trends and determinants in cardiovascular diseases in China, Part I: Morbidity and mortality monitoring. Circulation, 103, 462-468. doi:10.1161/01.CIR.103.3.462
[5]	Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults (2007) Chinese guidelines on prevention and treatment of dyslipidemia in adults. Chinese Journal of Cardiology, 35, 390-419.
[6]	Zhou, J.C., Zhao, H.C., Pan, K.H., et al. (2011) Current recognition and management of intra-abdominal hypertension and abdominal compartment syndrome among tertiary Chinese intensive care physicians. Journal of Zhejiang University SCIENCE B, 12, 156-162. doi:10.1631/jzus.B1000185
[7]	Bi, Y., Gao, R., Patel, A., et al. (2009) Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: Results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study. American Heart Journal, 157, 509e1-516e1.
[8]	Liu, Q., Zhao, D., Liu, J., et al. (2009) Current clinical practice patterns and outcome for acute coronary syndromes in China: Results of BRIG project. Zhonghua Xin Xue Guan Bing Za Zhi, 37, 213-217.
[9]	Song, X.T., Chen, Y.D., Pan, W.Q., et al. (2007) Gender based differences in patients with acute coronary syndrome: Findings from Chinese Registry of Acute Coronary Events (CRACE). Chinese Medical Journal (English Edition), 120, 1063-1067.
[10]	Hu, D., Li, J. and Li, X. (2008) Investigation of blood lipid levels and statin interventions in outpatients with coronary heart disease in China: The China Cholesterol Education Program (CCEP). Circulation Journal, 72, 2040-2045. doi:10.1253/circj.CJ-08-0417
[11]	Jiang, L., Armitage, J., Chen, Y., et al. (2010) Low use of statins among high-risk patients in China. World Heart Forum, 2010.
[12]	Li, J., Jiang, L., Li, X., et al. (2010) Cross-sectional study of statin use among high-risk patients with coronary heart disease in China. Chinese Circulation Journal, 25, 348- 351.
[13]	Jiang, L., Li, J., Feng, F., et al. (2010) Survey of statin usage in 4429 diabetic patients with atherosclerostic cardiovascular disease in China. Chinese Journal of Cardiovascular Medicine, 15, 264-268.
[14]	Jiang, L.X., Li, X., Li, J., et al. (2010) A cross-sectional study on the use of statin among patients with atherosclerotic ischemic stroke in China. Chinese Medical Journal, 31, 925-928.
[15]	Gao, R., Patel, A., Gao, W., et al. (2007) Prospective observational study of acute coronary syndromes in China: Practice patterns and outcomes. Heart, 94, 554-560. doi:10.1136/hrt.2007.119750
[16]	COMMIT Collaborative Group (2000) Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): A randomized trial of clopidogrel plus aspirin, and of metertiaryrolol, among patients with suspected acute myocardial infarction. Journal of Cardiovascular Risk, 7, 435-441.
[17]	COMMIT Collaborative Group (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet, 366, 1607-1621. doi:10.1016/S0140-6736(05)67660-X
[18]	COMMIT Collaborative Group (2005) Early intravenous then oral metertiaryrolol in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet, 366, 1622-1632. doi:10.1016/S0140-6736(05)67661-1
[19]	Gao, R., Patel, A., Gao, W., et al. (2008) Prospective observational study of acute coronary syndromes in China: Practice patterns and outcomes. Heart, 94, 554- 560. doi:10.1136/hrt.2007.119750
[20]	Fox, K.A., Goodman, S.G., Anderson, F.A. Jr., et al. (2003) From guidelines to clinical practice: The impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). European Heart Journal, 24, 1414-1424. doi:10.1016/S0195-668X(03)00315-4
[21]	Steg, P.G., Goldberg, R.J., Gore, J.M., et al. (2002) Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). American Journal of Cardiology, 90, 358-363. doi:10.1016/S0002-9149(02)02489-X
[22]	Mehta, S.R., Yusuf, S., Diaz, R., et al. (2005) Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: The CREATE-ECLA randomized controlled trial. Journal of the American Medical Association, 293, 437- 446. doi:10.1001/jama.293.4.437
[23]	Gao, R. (2010) Current status of percutaneous coronary intervention in China. Heart, 96, 415-418. doi:10.1136/hrt.2009.170571
[24]	Jiang, L.X., Chen, Z., Xie, J.X., et al. (2002) Survey of hospital management of myocardial infarction in China. Clinical Cardiology, 18, 3.
[25]	Tan, H.Q., Zhu, J., Liang, Y., et al. (2005) Two year follow-up of acute ischemic syndrome without ST elevation. National Medical Journal of China, 85, 184-188.
[26]	Group HPSC (2002) MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 360, 23-33. doi:10.1016/S0140-6736(02)09328-5
[27]	Cannon, C.P., Braunwald, E., McCabe, C.H., et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England Journal of Medicine, 350, 1495-1504. doi:10.1056/NEJMoa040583
[28]	Wang, H., Xu, T. and Xu, J. (2007) Factors contributing to high costs and inequality in China’s health care system. Journal of the American Medical Association, 298, 1928- 1930. doi:10.1001/jama.298.16.1928
[29]	Jonathan, W. (2008) Chen Zhu: From barefoot doctor to China’s Minister of Health. Lancet, 372, 1455.
[30]	Yip, W., Hiso, W., Meng, Q., et al. (2010) Realignment of incentives for health-care providers in China. Lancet, 375, 1120-1130. doi:10.1016/S0140-6736(10)60063-3